Several nonprofit organizations and coalitions have signed anopen letter to the U.S. Food and Drug Administration (FDA) and Gilead Sciencesurging them not to delay approval of Truvada, which is made by Gilead, for pre-exposureprophylaxis (PrEP) for men who have sex with men (MSM) and transgender people,according to a statement by the AIDS Vaccine Advocacy Coalition (AVAC). Gilead isseeking FDA approval of Truvada as an HIV prevention in both MSM andheterosexual people; it plans to combine the request for each groups into asingle filing. The signers are concerned that reviewing the data forheterosexual people will unnecessarily delay access to PrEP by MSM. The signersinclude AIDS Action Committee of Massachusetts, AIDS Foundation of Chicago,AIDS Research Consortium of Atlanta, AIDS United, AVAC, Black AIDS Institute,Fenway Health, GMHC, Harlem United, International Rectal MicrobicidesAdvocates, National Minority AIDS Council, Project Inform and San FranciscoAIDS Foundation.

To read the open letter, click here.